No abstract available
MeSH terms
-
Cost-Benefit Analysis
-
Drug Evaluation
-
Emergency Treatment / economics
-
Fibrinolytic Agents / adverse effects
-
Fibrinolytic Agents / classification
-
Fibrinolytic Agents / economics*
-
Fibrinolytic Agents / therapeutic use*
-
Hospitalization / economics
-
Humans
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / economics
-
Randomized Controlled Trials as Topic
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / economics
-
Recombinant Proteins / therapeutic use
-
Streptokinase / adverse effects
-
Streptokinase / economics
-
Streptokinase / therapeutic use
-
Tenecteplase
-
Thrombolytic Therapy / economics*
-
Time Factors
-
Tissue Plasminogen Activator / adverse effects
-
Tissue Plasminogen Activator / economics
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Outcome
Substances
-
Fibrinolytic Agents
-
Recombinant Proteins
-
reteplase
-
Streptokinase
-
Tissue Plasminogen Activator
-
Tenecteplase